Drug sensitivity profiling of 3D tumor tissue cultures in the pediatric precision oncology program INFORM.


Journal

NPJ precision oncology
ISSN: 2397-768X
Titre abrégé: NPJ Precis Oncol
Pays: England
ID NLM: 101708166

Informations de publication

Date de publication:
27 Dec 2022
Historique:
received: 05 05 2022
accepted: 29 11 2022
entrez: 27 12 2022
pubmed: 28 12 2022
medline: 28 12 2022
Statut: epublish

Résumé

The international precision oncology program INFORM enrolls relapsed/refractory pediatric cancer patients for comprehensive molecular analysis. We report a two-year pilot study implementing ex vivo drug sensitivity profiling (DSP) using a library of 75-78 clinically relevant drugs. We included 132 viable tumor samples from 35 pediatric oncology centers in seven countries. DSP was conducted on multicellular fresh tumor tissue spheroid cultures in 384-well plates with an overall mean processing time of three weeks. In 89 cases (67%), sufficient viable tissue was received; 69 (78%) passed internal quality controls. The DSP results matched the identified molecular targets, including BRAF, ALK, MET, and TP53 status. Drug vulnerabilities were identified in 80% of cases lacking actionable (very) high-evidence molecular events, adding value to the molecular data. Striking parallels between clinical courses and the DSP results were observed in selected patients. Overall, DSP in clinical real-time is feasible in international multicenter precision oncology programs.

Identifiants

pubmed: 36575299
doi: 10.1038/s41698-022-00335-y
pii: 10.1038/s41698-022-00335-y
pmc: PMC9794727
doi:

Types de publication

Journal Article

Langues

eng

Pagination

94

Informations de copyright

© 2022. The Author(s).

Références

Cancers (Basel). 2021 Sep 05;13(17):
pubmed: 34503286
ESMO Open. 2021 Dec;6(6):100319
pubmed: 34837746
Cancers (Basel). 2022 Feb 08;14(3):
pubmed: 35159116
BMC Cancer. 2015 Jul 15;15:519
pubmed: 26169261
J Vis Exp. 2017 Mar 7;(121):
pubmed: 28362421
Neuro Oncol. 2019 Feb 19;21(3):326-336
pubmed: 30418623
Cell Death Dis. 2017 Aug 24;8(8):e3013
pubmed: 28837150
Cancer Discov. 2017 May;7(5):462-477
pubmed: 28331002
Sci Rep. 2014 Jun 05;4:5193
pubmed: 24898935
Nat Med. 2017 Sep 8;23(9):1028-1035
pubmed: 28886003
Nucleic Acids Res. 2020 Jul 2;48(W1):W509-W514
pubmed: 32442275
Pediatr Blood Cancer. 2012 Sep;59(3):511-7
pubmed: 22147459
Cancer Discov. 2021 Nov;11(11):2764-2779
pubmed: 34373263
Cancer Res. 2016 Sep 15;76(18):5523-37
pubmed: 27635046
Nat Med. 2019 Sep;25(9):1422-1427
pubmed: 31406350
Oncotarget. 2016 May 10;7(19):27946-58
pubmed: 27056887
Cancer Discov. 2013 Dec;3(12):1416-29
pubmed: 24056683
Br J Cancer. 2020 May;122(10):1544-1551
pubmed: 32203216
EMBO Mol Med. 2022 Apr 7;14(4):e14608
pubmed: 34927798
Oncogene. 2017 Apr 20;36(16):2255-2264
pubmed: 27748766
Analyst. 2011 Feb 7;136(3):473-8
pubmed: 20967331
Future Oncol. 2018 Sep;14(21):2115-2129
pubmed: 29595064
Cancer Discov. 2022 Feb;12(2):388-401
pubmed: 34789538
JCO Precis Oncol. 2021 Oct 27;5:
pubmed: 34738048
Cancer Discov. 2021 Dec 1;11(12):3008-3027
pubmed: 34301788
Nat Commun. 2021 Jan 21;12(1):498
pubmed: 33479225
Nucleic Acids Res. 2009 Oct;37(18):e119
pubmed: 19589807
Eur J Cancer. 2020 May;130:168-181
pubmed: 32224415
Nature. 2017 Sep 7;549(7670):96-100
pubmed: 28854174
Cancer Discov. 2022 Feb;12(2):372-387
pubmed: 34635570
J Hematol Oncol. 2022 Jul 13;15(1):91
pubmed: 35831864
Cancer Discov. 2022 May 2;12(5):1266-1281
pubmed: 35292802
J Hematol Oncol. 2021 Sep 28;14(1):157
pubmed: 34583722
Nature. 2018 Mar 22;555(7697):469-474
pubmed: 29539639
BMC Bioinformatics. 2017 Feb 13;18(1):105
pubmed: 28193155
Eur J Cancer. 2016 Sep;65:91-101
pubmed: 27479119
Clin Cancer Res. 2017 Oct 15;23(20):6101-6112
pubmed: 28733441
Cell Rep. 2017 Dec 12;21(11):3298-3309
pubmed: 29241554
Nat Med. 2020 Nov;26(11):1742-1753
pubmed: 33020650
Pharmacol Res. 2022 Jan;175:105996
pubmed: 34848323
Int J Cancer. 2015 Feb 15;136(4):E173-87
pubmed: 25123598
Nat Commun. 2020 Aug 28;11(1):4324
pubmed: 32859926
Nat Commun. 2013;4:2612
pubmed: 24113773
Mol Cancer Ther. 2021 Aug;20(8):1400-1411
pubmed: 34088831

Auteurs

Heike Peterziel (H)

Hopp Children's Cancer Center Heidelberg (KiTZ), 69120, Heidelberg, Germany.
Clinical Cooperation Unit Pediatric Oncology, German Cancer Research Center (DKFZ) and German Cancer Consortium (DKTK), 69120, Heidelberg, Germany.
National Center for Tumor Diseases (NCT), 69120, Heidelberg, Germany.

Nora Jamaladdin (N)

Hopp Children's Cancer Center Heidelberg (KiTZ), 69120, Heidelberg, Germany.
Clinical Cooperation Unit Pediatric Oncology, German Cancer Research Center (DKFZ) and German Cancer Consortium (DKTK), 69120, Heidelberg, Germany.
National Center for Tumor Diseases (NCT), 69120, Heidelberg, Germany.
Faculty of Biosciences, Heidelberg University, 69120, Heidelberg, Germany.

Dina ElHarouni (D)

Hopp Children's Cancer Center Heidelberg (KiTZ), 69120, Heidelberg, Germany.
Faculty of Biosciences, Heidelberg University, 69120, Heidelberg, Germany.
Bioinformatics and Omics Data Analytics, German Cancer Research Center (DKFZ), 69120, Heidelberg, Germany.
Division of Pediatric Neurooncology, German Cancer Research Center (DKFZ) and German Cancer Consortium (DKTK), 69120, Heidelberg, Germany.

Xenia F Gerloff (XF)

Hopp Children's Cancer Center Heidelberg (KiTZ), 69120, Heidelberg, Germany.
Clinical Cooperation Unit Pediatric Oncology, German Cancer Research Center (DKFZ) and German Cancer Consortium (DKTK), 69120, Heidelberg, Germany.
National Center for Tumor Diseases (NCT), 69120, Heidelberg, Germany.
Faculty of Mathematics and Computer Science, Heidelberg University, 69120, Heidelberg, Germany.

Sonja Herter (S)

Hopp Children's Cancer Center Heidelberg (KiTZ), 69120, Heidelberg, Germany.
Clinical Cooperation Unit Pediatric Oncology, German Cancer Research Center (DKFZ) and German Cancer Consortium (DKTK), 69120, Heidelberg, Germany.
National Center for Tumor Diseases (NCT), 69120, Heidelberg, Germany.
Faculty of Biosciences, Heidelberg University, 69120, Heidelberg, Germany.

Petra Fiesel (P)

Hopp Children's Cancer Center Heidelberg (KiTZ), 69120, Heidelberg, Germany.
Clinical Cooperation Unit Neuropathology, German Cancer Research Center (DKFZ), German Consortium for Translational Cancer Research (DKTK), 69120, Heidelberg, Germany.

Yannick Berker (Y)

Hopp Children's Cancer Center Heidelberg (KiTZ), 69120, Heidelberg, Germany.
Clinical Cooperation Unit Pediatric Oncology, German Cancer Research Center (DKFZ) and German Cancer Consortium (DKTK), 69120, Heidelberg, Germany.
National Center for Tumor Diseases (NCT), 69120, Heidelberg, Germany.

Mirjam Blattner-Johnson (M)

Hopp Children's Cancer Center Heidelberg (KiTZ), 69120, Heidelberg, Germany.
Division of Pediatric Glioma Research, German Cancer Research Center (DKFZ) and German Cancer Consortium (DKTK), 69120, Heidelberg, Germany.

Kathrin Schramm (K)

Hopp Children's Cancer Center Heidelberg (KiTZ), 69120, Heidelberg, Germany.
Division of Pediatric Glioma Research, German Cancer Research Center (DKFZ) and German Cancer Consortium (DKTK), 69120, Heidelberg, Germany.

Barbara C Jones (BC)

Hopp Children's Cancer Center Heidelberg (KiTZ), 69120, Heidelberg, Germany.
Division of Pediatric Glioma Research, German Cancer Research Center (DKFZ) and German Cancer Consortium (DKTK), 69120, Heidelberg, Germany.
Department of Pediatric Oncology, Hematology, Immunology and Pulmonology, Heidelberg University Hospital, 69120, Heidelberg, Germany.

David Reuss (D)

Department Neuropathology at Institute of Pathology, Heidelberg University Hospital, 69120, Heidelberg, Germany.
Clinical Cooperation Unit Neuropathology, German Cancer Research Center (DKFZ), German Consortium for Translational Cancer Research (DKTK), 69120, Heidelberg, Germany.

Laura Turunen (L)

Institute for Molecular Medicine Finland (FIMM), Helsinki Institute of Life Science (HiLIFE), University of Helsinki, 00014, Helsinki, Finland.

Aileen Friedenauer (A)

Hopp Children's Cancer Center Heidelberg (KiTZ), 69120, Heidelberg, Germany.
Clinical Cooperation Unit Pediatric Oncology, German Cancer Research Center (DKFZ) and German Cancer Consortium (DKTK), 69120, Heidelberg, Germany.
National Center for Tumor Diseases (NCT), 69120, Heidelberg, Germany.

Tim Holland-Letz (T)

Division of Biostatistics, German Cancer Research Center (DKFZ), Heidelberg, Germany.

Martin Sill (M)

Hopp Children's Cancer Center Heidelberg (KiTZ), 69120, Heidelberg, Germany.
Division of Pediatric Neurooncology, German Cancer Research Center (DKFZ) and German Cancer Consortium (DKTK), 69120, Heidelberg, Germany.

Lena Weiser (L)

Core Facility Omics IT and Data Management (ODCF), German Cancer Research Center (DKFZ), 69120, Heidelberg, Germany.

Christopher Previti (C)

Hopp Children's Cancer Center Heidelberg (KiTZ), 69120, Heidelberg, Germany.
Division of Pediatric Neurooncology, German Cancer Research Center (DKFZ) and German Cancer Consortium (DKTK), 69120, Heidelberg, Germany.
Core Facility Omics IT and Data Management (ODCF), German Cancer Research Center (DKFZ), 69120, Heidelberg, Germany.

Gnanaprakash Balasubramanian (G)

Hopp Children's Cancer Center Heidelberg (KiTZ), 69120, Heidelberg, Germany.
Division of Pediatric Neurooncology, German Cancer Research Center (DKFZ) and German Cancer Consortium (DKTK), 69120, Heidelberg, Germany.

Nicolas U Gerber (NU)

Department of Oncology, University Children's Hospital Zürich, CH-8032, Zürich, Switzerland.

Johannes Gojo (J)

Department of Pediatrics and Adolescent Medicine, Comprehensive Cancer Center and Comprehensive Center for Pediatrics, Medical University of Vienna, 1090, Vienna, Austria.

Caroline Hutter (C)

St. Anna Children's Hospital, Department of Pediatrics and Adolescent Medicine, Medical University of Vienna, 1090, Vienna, Austria.
St. Anna Children's Cancer Research Institute (CCRI), Vienna, Austria.

Ingrid Øra (I)

Children's Hospital, Pediatric Oncology, Skåne University Hospital, Lund & Karolinska University Hospital, Stockholm, Sweden.

Olli Lohi (O)

Faculty of Medicine and Health Technology, Tampere Center for Child Health Research, Tampere University, Tampere, Finland, and Tays Cancer Center, Tampere University Hospital, Tampere, Finland.

Antonis Kattamis (A)

First Department of Pediatrics, National and Kapodistrian University of Athens, Athens, Greece.

Bram de Wilde (B)

Center for Medical Genetics, Ghent University, Ghent, Belgium.

Frank Westermann (F)

Hopp Children's Cancer Center Heidelberg (KiTZ), 69120, Heidelberg, Germany.
Division of Neuroblastoma Genomics, German Cancer Research Center, Heidelberg, Germany.

Stephan Tippelt (S)

Pediatrics III Pediatric Hematology, Oncology, Immunology, Cardiology, Pulmonology, West German Cancer Center; German Cancer Consortium (DKTK), University Hospital Essen, Essen, Germany.

Norbert Graf (N)

Department of Pediatric Oncology, Saarland University Medical Center, 66421, Homburg, Germany.

Michaela Nathrath (M)

Department of Pediatric Oncology, Klinikum Kassel, Kassel, Germany.
Department of Pediatrics and Children's Cancer Research Center, Klinikum rechts der Isar, Technical University of Munich, Munich, Germany.

Monika Sparber-Sauer (M)

Klinikum der Landeshauptstadt Stuttgart gKAöR, Olgahospital, Stuttgart Cancer Center, Zentrum für Kinder-, Jugend- und Frauenmedizin, Pädiatrie 5 (Pädiatrische Onkologie, Hämatologie, Immunologie), Stuttgart, Germany.
University of Medicine Tübingen, Tübingen, Germany.

Astrid Sehested (A)

Department of Pediatrics and Adolescent Medicine, Rigshospitalet, Copenhagen, Denmark.

Christof M Kramm (CM)

Division of Pediatric Hematology and Oncology, University Medical Center Göttingen, Göttingen, Germany.

Uta Dirksen (U)

Pediatrics III Pediatric Hematology, Oncology, Immunology, Cardiology, Pulmonology, West German Cancer Center; German Cancer Consortium (DKTK), University Hospital Essen, Essen, Germany.

Olli Kallioniemi (O)

Institute for Molecular Medicine Finland (FIMM), Helsinki Institute of Life Science (HiLIFE), University of Helsinki, 00014, Helsinki, Finland.
iCAN Digital Precision Cancer Medicine Flagship, University of Helsinki, Helsinki, FI-00014, Finland.

Stefan M Pfister (SM)

Hopp Children's Cancer Center Heidelberg (KiTZ), 69120, Heidelberg, Germany.
Division of Pediatric Neurooncology, German Cancer Research Center (DKFZ) and German Cancer Consortium (DKTK), 69120, Heidelberg, Germany.
Department of Pediatric Oncology, Hematology, Immunology and Pulmonology, Heidelberg University Hospital, 69120, Heidelberg, Germany.

Cornelis M van Tilburg (CM)

Hopp Children's Cancer Center Heidelberg (KiTZ), 69120, Heidelberg, Germany.
Clinical Cooperation Unit Pediatric Oncology, German Cancer Research Center (DKFZ) and German Cancer Consortium (DKTK), 69120, Heidelberg, Germany.
National Center for Tumor Diseases (NCT), 69120, Heidelberg, Germany.
Department of Pediatric Oncology, Hematology, Immunology and Pulmonology, Heidelberg University Hospital, 69120, Heidelberg, Germany.

David T W Jones (DTW)

Hopp Children's Cancer Center Heidelberg (KiTZ), 69120, Heidelberg, Germany.
Division of Pediatric Glioma Research, German Cancer Research Center (DKFZ) and German Cancer Consortium (DKTK), 69120, Heidelberg, Germany.

Jani Saarela (J)

Institute for Molecular Medicine Finland (FIMM), Helsinki Institute of Life Science (HiLIFE), University of Helsinki, 00014, Helsinki, Finland.

Vilja Pietiäinen (V)

Institute for Molecular Medicine Finland (FIMM), Helsinki Institute of Life Science (HiLIFE), University of Helsinki, 00014, Helsinki, Finland.
iCAN Digital Precision Cancer Medicine Flagship, University of Helsinki, Helsinki, FI-00014, Finland.

Natalie Jäger (N)

Hopp Children's Cancer Center Heidelberg (KiTZ), 69120, Heidelberg, Germany.
Division of Pediatric Neurooncology, German Cancer Research Center (DKFZ) and German Cancer Consortium (DKTK), 69120, Heidelberg, Germany.

Matthias Schlesner (M)

Bioinformatics and Omics Data Analytics, German Cancer Research Center (DKFZ), 69120, Heidelberg, Germany.
Biomedical Informatics, Data Mining and Data Analytics, Faculty of Applied Computer Science and Medical Faculty, University of Augsburg, Augsburg, Germany.

Annette Kopp-Schneider (A)

Division of Biostatistics, German Cancer Research Center (DKFZ), Heidelberg, Germany.

Sina Oppermann (S)

Hopp Children's Cancer Center Heidelberg (KiTZ), 69120, Heidelberg, Germany.
Clinical Cooperation Unit Pediatric Oncology, German Cancer Research Center (DKFZ) and German Cancer Consortium (DKTK), 69120, Heidelberg, Germany.
National Center for Tumor Diseases (NCT), 69120, Heidelberg, Germany.

Till Milde (T)

Hopp Children's Cancer Center Heidelberg (KiTZ), 69120, Heidelberg, Germany.
Clinical Cooperation Unit Pediatric Oncology, German Cancer Research Center (DKFZ) and German Cancer Consortium (DKTK), 69120, Heidelberg, Germany.
National Center for Tumor Diseases (NCT), 69120, Heidelberg, Germany.
Department of Pediatric Oncology, Hematology, Immunology and Pulmonology, Heidelberg University Hospital, 69120, Heidelberg, Germany.

Olaf Witt (O)

Hopp Children's Cancer Center Heidelberg (KiTZ), 69120, Heidelberg, Germany.
Clinical Cooperation Unit Pediatric Oncology, German Cancer Research Center (DKFZ) and German Cancer Consortium (DKTK), 69120, Heidelberg, Germany.
National Center for Tumor Diseases (NCT), 69120, Heidelberg, Germany.
Department of Pediatric Oncology, Hematology, Immunology and Pulmonology, Heidelberg University Hospital, 69120, Heidelberg, Germany.

Ina Oehme (I)

Hopp Children's Cancer Center Heidelberg (KiTZ), 69120, Heidelberg, Germany. i.oehme@kitz-heidelberg.de.
Clinical Cooperation Unit Pediatric Oncology, German Cancer Research Center (DKFZ) and German Cancer Consortium (DKTK), 69120, Heidelberg, Germany. i.oehme@kitz-heidelberg.de.
National Center for Tumor Diseases (NCT), 69120, Heidelberg, Germany. i.oehme@kitz-heidelberg.de.

Classifications MeSH